Nanomedicine seeks solutions against rare diseases

Despite its importance in the fight against pandemics such as COVID-19, a lesser-known face of nanomedicine is its potential to contribute to solutions to so-called rare or minority diseases. Coinciding with February 28th, the world day for rare diseases, experts invited by the Nanomed Spain platform and the Sant Joan de Déu Research Institute (IRSJD) present the latest advances in nanomedicine against three of these disorders: muscular dystrophy, cystic fibrosis and Fabry disease.

BiofilmChip protagonist in the media

Researchers from the Institute for Bioengineering of Catalonia (IBEC), led by Eduard Torrents, leader of the group “bacterial infections and antimicrobial therapies” and professor at the University of Barcelona (UB), in collaboration with Josep Samitier, principal investigator of the group “Nanobioingineering” of IBEC, and Maite Martin, of the Vall d’Hebron Barcelona Hospital appear in the media for the new device, called BiofilmChip, which allows a custom and precise diagnosis of chronic infections.

A chip against chronic bacterial infections

IBEC researchers develop a device that allows to grow biofilms and analyze their susceptibility to different antibiotics in a simple way and using patient samples. BiofilmChip, a low-cost, easy-to-use diagnostic device, opens the way to finding effective and custom treatments against chronic infections produced by biofilms.

An alternative to mice for toxicity testing

Eduard Torrents and his team present an alternative to experimentation with mice. The research proposes the use of waxworms to evaluate the toxicity of nanoparticles, which is also cheaper and more ethical. These insects allow us to model their possible nanotoxicity in a living organism.

IBEC researchers propose a cheaper and more ethical model for toxicological studies

A new study by IBEC’s Bacterial Infections: Antimicrobial Therapies and Molecular and cellular neurobiotechnology groups shows that Galleria mellonella larvae can be effective to test the toxicity of nanoparticles. This work thus paves the way toward a new animal model for toxicity studies that represent an inexpensive and more ethical alternative to rodent testing.